|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2017-08-24 |
|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2017-05-08 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2014-04-23 |
An open-label, multi-center, roll-over study to assess long term safety inpatients with endogenous Cushing’s syndrome who have completed a priorNovartis-sponsored osilodrostat (LCI699) study and are judged by theinvestigator to benefit from continued treatment with osilodrostat. - NA
An open label, multi-center pasireotide roll-over protocolfor patients who have completed a previous Novartissponsoredpasireotide study and are judged by theinvestigator to benefit from continued pasireotidetreatment.
An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat
100 项与 Recordati AG 相关的临床结果
0 项与 Recordati AG 相关的专利(医药)
100 项与 Recordati AG 相关的药物交易
100 项与 Recordati AG 相关的转化医学